ALK-Abello A/S 2008 AR2
The report highlights ALK's financial and operational performance for the fiscal year 2008, during which the company achieved 12% organic growth in allergy vaccine sales. Key milestones included breakthrough research results for its tablet-based allergy vaccine GRAZAX®, which demonstrated sustained long-term efficacy, and positive clinical study results for its house dust mite allergy tablet. Additionally, GRAZAX® received regulatory approval for children and adolescents in 27 European countries. On the sustainability front, ALK reduced its relative energy and water consumption and waste generation, while also lowering its occupational injury frequency to 5.1 per million working hours.
Company: ALK-Abello A/S
Sector: Manufacturing
Country: Denmark
Year: 2008
Type: AR2
Pages: 76
Back to company
ALK-Abello A/S
Annual Report
The report highlights ALK's financial and operational performance for the fiscal year 2008, during which the company achieved 12% organic growth in allergy vaccine sales. Key milestones included breakthrough research results for its tablet-based allergy vaccine GRAZAX®, which demonstrated sustained long-term efficacy, and positive clinical study results for its house dust mite allergy tablet. Additionally, GRAZAX® received regulatory approval for children and adolescents in 27 European countries. On the sustainability front, ALK reduced its relative energy and water consumption and waste generation, while also lowering its occupational injury frequency to 5.1 per million working hours.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2008
Reporting Period
Jan 1, 2008 - Dec 31, 2008
Fiscal Year
2008
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Employees